Current Non-Tuberculosis Mycobacterial Lung Disease Trials
Learn about our active studies for individuals with non-tuberculosis mycobacterial lung disease. Our research team is happy to answer any questions you might have about these clinical trials.
Interested in Enrolling in a Clinical Study?
PLEASE CLICK HERE AND COMPLETE THE CLINICAL STUDY INTEREST FORM
Information on current studies may be found by choosing a title below:
MKC-CI-002 – ICoN-1
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101 (Clofazimine Inhalation Suspension) When Added to Guideline-Based Therapy in Participants with Pulmonary Nontuberculous Mycobacterial Infection (Part A) Followed by an Open-Label Extension (Part B)
- Enrollment Status: Recruiting
- Study Type: Observational (Clinical Trial)
- Intervention/Treatment: MNKD-101 (Clofazimine Inhalation Suspension) / or placebo
- Sponsor: The University of Kansas Medical Center
- PI: Andreas Schmid, MD
Insmed 19145
Qualitative Interviews to Support PRO Measurement Development in Patients with Mycobacterium avium complex (MAC) or Mycobacterium abscessus (MAbs) Lung Infection
- Enrollment Status: Completed
- Study Type: Qualitative Assessment
- Intervention/Treatment: N/A
- Sponsor: Insmed Incorporated
- PI: Andreas Schmid, M.D.
INS-415 – ARISE
ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)
- Enrollment Status: Completed
- Study Type: Interventional (Clinical Trial)
- Intervention/Treatment: ALIS / Azithromycin / Ethambutol / ELC
- Sponsor: Insmed Incorporated
- PI: Andreas Schmid, M.D.
INS-416 – ENCORE
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)
- Enrollment Status: Recruiting
- Study Type: Interventional (Clinical Trial)
- Intervention/Treatment: Drug: ALIS / Azithromycin / Ethambutol / ELC (matching placebo for ALIS)
- Sponsor: Insmed Incorporated
- PI: Andreas Schmid, M.D.